Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

While the previous PATHFINDER study—a prospective, year-long examination of about 6,600 people—showed that Galleri could more ...

Back in May 2025, dapiglutide failed to impress in a phase 2 trial, mustering up to an average 4.3% reduction in weight loss when given at the 6 mg dose. The 54-person study involved administering ...